How Rare Is Too Rare? Redefining Viability for Ultra-Rare Disease Therapeutics

Key Takeaways
Ultra-rare drug development is shifting from a scientific feasibility question to a systems challenge shaped by regulatory evidence standards, EU Joint Clinical Assessment (JCA) pathways, and U.S. Medicaid payment models for cell and gene therapies.
Regulators now explicitly recognize that randomized controlled trials are often infeasible in ultra-rare populations, driving increased reliance on natural history studies, registries, surrogate endpoints, and externally controlled trial designs.
In Europe, the phased rollout of JCA will standardize how clinical evidence for ultra-rare and advanced therapies is evaluated before national reimbursement decisions, raising the importance of real-world and nontraditional data.
In the United States, outcomes-based contracts and value-based purchasing reforms in Medicaid are redefining commercial viability by linking payment for ultra-rare therapies directly to real-world patient outcomes.

Why “How Rare Is Too Rare?” Is Being Asked Again

For much of the modern orphan drug era, a central question was whether it was scientifically and financially possible to develop therapies for very small patient populations at all. That threshold has shifted. Advances in molecular diagnostics, cell and gene therapy platforms, and regulatory science have made it technically feasible to target conditions once considered unreachable. As a result, the strategic question facing sponsors and their manufacturing partners is no longer simply whether a therapy can be developed but whether it can be developed in a way that is viable across regulatory approval, evidence expectations, and commercial access.

The term “ultra-rare” itself reflects this shift in scale. In industry and policy discussions, it is often associated with prevalence levels on the order of one in 50,000 people, with some conditions affecting as few as one in one million. At these population sizes, traditional development assumptions begin to break down. Recruiting hundreds of patients into randomized trials becomes impractical or impossible, and even defining meaningful clinical endpoints can require rethinking how disease progression is measured and compared across individuals.

Regulators have increasingly acknowledged these constraints explicitly. Guidance for small populations in the European Union notes that for some rare diseases, only a few thousand (or in some cases fewer than 100) patients may be available, making conventional trial designs unworkable.¹ Rather than treating this as an exception, agencies have begun to formalize alternative approaches to evidence generation, including the use of registries, natural history data, surrogate endpoints, and externally controlled trials. This evolution signals that “too rare” is no longer a scientific boundary so much as a problem of methodology and infrastructure.

At the same time, the definition of viability has expanded beyond regulatory approval alone. In the European Union, the introduction of Joint Clinical Assessments (JCAs) under the Health Technology Assessment Regulation creates a new layer of coordinated clinical evidence review that sits between authorization and national reimbursement decisions.2 In the United States, public payers are experimenting with outcomes-based agreements for cell and gene therapies through the CMS Cell and Gene Therapy Access Model, explicitly linking payment to patient outcomes for ultra-high-cost, one-time treatments.³ These developments do not change the underlying rarity of the diseases being targeted, but they do change how uncertainty, cost, and evidence are managed once a product reaches the market.

The calculus around ultra-rare disease development is shifting: what was once framed primarily as a moral or public health imperative is increasingly treated as a strategic decision grounded in trial feasibility, assessment standards, and payment mechanisms. The renewed question — How rare is too rare? — reflects this convergence. It is no longer answered solely by biology or prevalence statistics, but by whether the surrounding regulatory and commercial systems can support therapies designed for populations measured in the hundreds or even the dozens.

What Does “Ultra-Rare” Mean in Practice?

Despite its frequent use in scientific, regulatory, and commercial discussions, “ultra-rare” does not have a single, universally accepted definition. Instead, it is a descriptive label built upon several formal policy thresholds that were originally designed for “rare diseases” more broadly. A systematic review of global rare disease and orphan drug definitions shows wide variation in how rarity and ultra-rarity are defined across jurisdictions and institutions, reflecting different policy objectives and health system structures.⁴ This lack of uniformity means that whether a disease is considered merely rare or truly ultra-rare often depends on which regulatory or reimbursement framework is being applied.

In the European Union, the legal anchor point is orphan designation rather than an explicit “ultra-rare” category. Under this framework, a condition qualifies as rare if it affects no more than five in 10,000 people in the EU, or if it is unlikely to generate sufficient return on investment to justify development without incentives. In addition to prevalence, eligibility requires that the disease be life-threatening or chronically debilitating and that either no satisfactory treatment exists or the proposed therapy provides significant benefit over existing options.⁵ These criteria establish a formal boundary for rarity but do not distinguish between diseases affecting several thousand patients and those affecting only a few dozen.

In the United States, the definition is framed differently. Rather than using a prevalence rate, rare diseases are defined by an absolute patient count: conditions that affect fewer than 200,000 people nationwide. This threshold underpins orphan drug designation and the associated incentives administered by the U.S. Food and Drug Administration (FDA).⁶ As in the EU, this definition captures a broad range of diseases with very different population sizes and development challenges.

Because neither the EU nor the U.S. regulatory frameworks formally define “ultra-rare,” the term has emerged as a secondary reference point, often shaped by health technology assessment and coverage discussions. The United Kingdom’s National Institute for Health and Care Excellence (NICE) provides one of the clearest operational examples. Its routing criteria for Highly Specialised Technologies define ultra-rare conditions as those affecting one in 50,000 people or fewer. Although this definition is specific to the UK context, it is frequently cited in broader international conversations about how to evaluate therapies for extremely small patient populations.⁷

Owing to the absence of structured definitions, “ultra-rare” is best understood as a practical concept rather than a statutory one. EU and U.S. policies establish boundaries for what counts as rare, while organizations such as NICE introduce finer distinctions that reflect the realities of evidence generation and reimbursement for very small populations. For sponsors and their partners, this patchwork of definitions means that rarity is not a single number but a spectrum, shaped by regulatory eligibility, economic justification, and assessment pathways that vary by region.

How Ultra-Rare Development Became Possible at All

U.S. Orphan Incentives

The modern landscape of ultra-rare disease development rests on a set of policy tools designed to offset the scientific and commercial risks associated with very small patient populations. In the United States, these tools are rooted in the orphan drug framework, which provides sponsors with a defined package of regulatory and financial incentives once a product receives orphan designation.

Among the most consequential of these incentives is a seven-year period of market exclusivity following approval for the designated indication. During this period, the FDA will not approve the same drug for the same use from another sponsor, even in the absence of patent protection. This exclusivity operates independently of intellectual property and was created specifically to encourage investment in diseases that would otherwise be unattractive from a market-size perspective.

Financial incentives further reduce the upfront burden of development. Orphan designation is associated with tax credits for qualified clinical testing expenses and exemptions from certain FDA user fees, which can represent a substantial cost for small or emerging companies. The designation helps lower the capital required to advance a program into and through clinical development, making it possible for sponsors to justify work on indications with extremely limited patient numbers.

For pediatric ultra-rare diseases, the incentive structure extends even further. The FDA’s Rare Pediatric Disease designation can qualify sponsors for Priority Review Vouchers upon approval. These vouchers allow a future drug application to receive expedited FDA review and can be used by the sponsor or sold to another company. In practice, this has created an additional, indirect economic return that can help offset the narrow commercial footprint of a pediatric ultra-rare therapy.⁶

While, these U.S. incentives transformed ultra-rare disease development from a philanthropic or academic pursuit into a viable commercial strategy, they did not eliminate scientific risk or operational complexity.

EU Orphan Incentives

A parallel but distinct framework emerged in the European Union, built around orphan medicinal product designation administered through the European Medicines Agency (EMA). As in the United States, the central feature of the EU system is market exclusivity. Orphan medicines benefit from 10 years of exclusivity after marketing authorization, during which similar products for the same indication generally cannot be approved. Under specific circumstances, such as when a product no longer meets the criteria for orphan status or when sufficient supply is not ensured, this exclusivity period may be reduced from 10 to six years.

Eligibility for orphan designation in the EU is defined by a combination of clinical and economic criteria. A condition must be life-threatening or chronically debilitating and must affect no more than five in 10,000 people in the European Union or be unlikely to generate sufficient return on investment without incentives. In addition, if satisfactory methods of treatment already exist, the proposed therapy must demonstrate a significant benefit over available alternatives. These requirements embed both public health need and comparative value into the designation process.

The EU framework also provides regulatory support beyond exclusivity alone. Sponsors can access scientific advice tailored to orphan products and benefit from reductions or waivers of certain regulatory fees. While these elements are less visible than market exclusivity, they play an important role in lowering development friction for programs that already face challenges in patient recruitment and evidence generation.

The Evidence Problem: Why Traditional Trials Break Down

Population Size as a Structural Constraint

At the scale of ultra-rare disease, the assumptions that drive conventional clinical development begin to fail. Regulatory guidance in the European Union recognizes that some rare diseases affect only a few thousand patients, and in certain cases fewer than 100 individuals may be identified worldwide. In these circumstances, the basic mechanics of randomized controlled trials — large sample sizes, parallel control arms, and statistical power — become extremely difficult to implement.¹

This limitation is structural as well as logistical. When the total number of patients eligible for study is small, enrolling hundreds of participants is often impossible regardless of trial design or geographic reach. Even multi-national recruitment efforts may struggle to assemble cohorts that meet traditional statistical expectations. As a result, the question is no longer how to optimize trial efficiency within standard paradigms, but how to generate interpretable evidence when patient numbers fall below the thresholds those paradigms were built to support.

These constraints are especially acute for conditions with early mortality, rapid progression, or highly heterogeneous clinical presentation. In such settings, delays associated with lengthy enrollment periods can undermine both scientific validity and ethical acceptability. Regulators have therefore begun to frame small population development as a distinct methodological challenge rather than a scaled-down version of common disease trials.

Endpoint Flexibility and Surrogates

As population size limits the feasibility of traditional trial designs, the choice of endpoints takes on heightened importance. U.S. guidance on rare disease drug development places explicit emphasis on endpoint selection as a central scientific issue, noting that conventional clinical outcomes may be difficult to measure or may require observation periods that are impractical in very small cohorts. Biomarkers and other surrogate endpoints are therefore treated as critical tools for demonstrating treatment effects when direct clinical measures are unavailable or insufficiently sensitive.⁸

This shift does not imply lower evidentiary standards but rather a different evidentiary strategy. The same guidance stresses the need for early interaction with regulators to determine whether proposed endpoints are reasonably likely to reflect meaningful clinical benefit. In ultra-rare settings, where disease trajectories may be poorly characterized, endpoint development often depends on parallel efforts to understand natural history and biological mechanisms, not simply on trial execution alone.

European guidance similarly highlights the role of surrogate endpoints and alternative data sources. The EMA’s framework for small populations explicitly references registries and epidemiological data as components of evidence generation and flags surrogate endpoints as a key methodological consideration. These tools are presented not as exceptions but as integral elements of development strategies for conditions in which traditional outcome measures are not feasible.⁹

These regulatory positions illustrate why ultra-rare disease development cannot rely on standard trial templates. Population size constrains enrollment, while disease biology constrains endpoint selection. The resulting evidence problem is not one of diminished rigor but of adaptation: finding scientifically credible ways to demonstrate benefit in contexts where the conventional architecture of clinical trials no longer applies.^1,8,9

Natural History, Registries, and External Controls

When patient populations are measured in dozens rather than hundreds, the traditional separation between clinical infrastructure and clinical evidence begins to break down. In ultra-rare disease development, systems built to observe and document disease progression — natural history studies, patient registries, and structured real-world data — often become central components of the evidentiary package rather than supplementary context.

U.S. guidance makes this shift explicit through its treatment of external controls. An externally controlled trial is defined as one in which outcomes in treated patients are compared with those observed in a group outside the trial who did not receive the investigational therapy. These control groups may be historical or concurrent and are frequently drawn from natural history data sets or disease registries rather than from prospectively randomized cohorts.^10,11 This approach reflects a recognition that in ultra-rare settings, withholding therapy from a contemporaneous control arm may be infeasible or ethically problematic, and that well-characterized observational data can provide a meaningful comparator when designed and curated appropriately.

In the European Union, registry-based studies are similarly elevated from supportive tools to formal instruments of regulatory decision-making. EMA guidance on registry-based studies outlines how such data can be used to support evaluations of safety and effectiveness, provided that study populations, protocols, and data quality systems are clearly defined and maintained. The guidance addresses issues ranging from governance and data collection methods to analytical approaches, underscoring that registries must be structured with regulatory use in mind rather than assembled solely for academic or advocacy purposes.¹²

This evolution places new demands on drug developers and their partners. Building registries and natural history programs requires early investment in data standards, longitudinal follow-up, and clinical engagement well before pivotal trials begin. In many cases, these efforts serve multiple functions at once: clarifying disease progression, informing endpoint selection, and supplying external control data that can contextualize treatment effects. What once might have been considered background research becomes part of the formal evidentiary framework submitted to regulators.

The growing reliance on natural history and registry infrastructure reflects a broader recalibration of what counts as acceptable evidence in ultra-rare disease development. Rather than forcing small populations into trial models designed for common diseases, regulators have articulated pathways that integrate observational data with interventional results. In this context, infrastructure itself becomes evidence: an organized means of translating limited patient experience into a coherent basis for regulatory judgment.

Single-Arm Trials and Accelerated Pathways

When RCTs Are Not Feasible

In ultra-rare disease development, the feasibility of randomized controlled trials (RCTs) is often constrained not by design ambition but by population reality. Regulatory guidance in both the United States and the European Union explicitly recognizes that conventional randomization and large control arms may be impractical when only a small number of patients can be identified and enrolled.

The U.S. framework formalizes this reality through its definition of externally controlled trials. These are studies in which outcomes observed in treated patients are compared against outcomes from a group outside the trial who did not receive the investigational therapy. The external comparator may be historical or concurrent and is frequently derived from natural history data sets or registries rather than from a prospectively randomized cohort.¹¹ This structure provides a way to contextualize treatment effects when an internal control arm cannot be justified scientifically or ethically.

European guidance similarly elevates the role of external controls in small populations. The EMA’s scientific guideline on clinical trials in small populations explicitly identifies external control approaches as a relevant methodological option when standard randomized designs are not workable. Rather than treating such designs as exceptional, the guidance positions them within a broader toolkit for generating interpretable evidence in diseases with very limited patient availability.¹

The growing reliance on single-arm and externally controlled designs reflects a shift in regulatory logic. The focus moves away from rigid adherence to trial architecture and toward the credibility of the comparison being made. The central question becomes whether the observed outcomes in treated patients can be meaningfully interpreted against a well-characterized external benchmark rather than whether randomization itself has been achieved.

Expedited Approval with Obligations

Single-arm and externally controlled trials are often paired with expedited regulatory pathways that allow earlier market access while requiring additional evidence after approval. In the United States, the Accelerated Approval Program provides a structured mechanism for this approach. Products may be approved based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit, with the explicit condition that sponsors conduct confirmatory studies to verify and describe the anticipated effect on patient outcomes.¹³

Recent guidance emphasizes that these post-approval obligations are not optional. Confirmatory trials must be underway within defined timeframes, and failure to demonstrate benefit can trigger regulatory actions that may ultimately lead to withdrawal of approval. Accelerated approval therefore trades earlier access for a continuing evidentiary commitment, rather than relaxing standards altogether.¹³

A parallel construct exists in the European Union through Conditional Marketing Authorization. This pathway allows medicines addressing unmet medical need to receive authorization based on less complete data than normally required, on the condition that comprehensive clinical information will be generated after approval. These obligations are legally binding and subject to regular review, ensuring that conditional access is coupled with an ongoing requirement to reduce uncertainty over time.¹⁴

Recent Regulatory Signals: Ultra-Rare Is Now a Policy Category

FDA Rare Disease Evidence Principles (RDEP)

In addition to adapting existing approval pathways, the FDA has begun to formalize how evidence for rare diseases should be generated and evaluated. The introduction of the Rare Disease Evidence Principles (RDEP) reflects an effort to bring greater clarity and consistency to regulatory decision-making in areas where traditional trial models do not readily apply. The agency described RDEP as a framework intended to improve both the speed and predictability of rare disease drug development by outlining the types of evidence that may be used to establish substantial effectiveness.¹⁵

Rather than prescribing a single development template, RDEP emphasizes a principles-based approach to evidence generation. This signals that ultra-rare disease programs will increasingly be assessed through a structured lens that takes into account disease biology, feasibility of enrollment, and the appropriateness of alternative data sources. In practice, this moves rare disease development away from ad hoc accommodation and toward a more standardized policy category with its own expectations and review logic. For sponsors and their partners, RDEP provides a clearer sense of how unconventional data sets (e.g., natural history studies, biomarkers, and externally controlled trials) may fit into a coherent regulatory narrative.

Sub-1,000 Patient Frameworks

Beyond general guidance, the FDA has also proposed pathways explicitly tailored to extremely small patient populations. Reporting in 2025 described a proposed process for diseases affecting fewer than 1,000 individuals in the United States, under which approval could potentially be supported by a single adequate study, including single-arm trials, when randomized designs are not feasible. The framework was presented as a way to accelerate access to therapies for ultra-rare genetic conditions with no adequate treatment alternatives.¹⁶

A related initiative focused on personalized therapies went even further, introducing a pathway that would allow approval based on data from only a handful of patients when there is a strong mechanistic rationale and a clear link between the therapy and the disease target. In this model, real-world evidence collected after approval would play a central role in confirming benefit and monitoring outcomes over time.¹⁷

These developments suggest that “ultra-rare” is no longer merely a descriptive label but an emerging policy construct. By creating guidance and proposed pathways that reference population size directly, the FDA is signaling that the challenges of sub-1,000 patient diseases warrant tailored evidentiary and procedural approaches. For developers of cell and gene therapies and other precision medicines, this represents a material change in how regulatory risk is defined: the question is no longer whether evidence can be generated at all, but whether it can be generated in a way that aligns with these newly articulated principles and pathways.

Commercial Viability: Approval Is Only the First Gate

EU HTA and Joint Clinical Assessment

For ultra-rare therapies, regulatory approval increasingly represents only the first step in determining whether a product can reach patients. In the European Union, the introduction of JCAs under Regulation (EU) 2021/2282 establishes a coordinated, EU-level process for evaluating the clinical evidence supporting new health technologies before national reimbursement decisions are made.² JCAs are intended to provide a scientific analysis of a product’s relative effects on health outcomes, creating a shared foundation of evidence that member states can use in their own health technology assessment (HTA) and pricing deliberations.

This framework is being implemented through a phased rollout that directly intersects with the types of products most often associated with ultra-rare disease development. Beginning in 2025, JCAs apply to new active substances for the treatment of cancer and to advanced therapy medicinal products (ATMPs), a category that includes many cell and gene therapies.¹⁸ Orphan medicinal products will enter the JCA process in 2028, followed by all other eligible medicinal products in 2030. The sequencing reflects a policy choice to prioritize areas of high innovation and clinical complexity while gradually expanding the scope of coordinated assessment across the pharmaceutical landscape.

For developers of ultra-rare and genetically targeted therapies, this timeline has practical implications. Evidence packages that may previously have been assembled primarily with regulators in mind must now also anticipate scrutiny through a standardized EU-level clinical assessment process. Although JCAs do not determine price or reimbursement directly, they shape the interpretation of clinical value that national HTA bodies will use in downstream decisions. In this sense, commercial viability becomes linked not only to meeting regulatory standards for approval but also to aligning evidence generation strategies with the expectations of a multi-country assessment framework.

HTA and Rare Disease Risk

The extension of JCA into rare and ultra-rare indications has prompted concern about how uncertainty will be handled in diseases where data are inherently limited. Peer-reviewed analyses have warned that if JCAs rely too narrowly on traditional evidentiary hierarchies and fail to incorporate real-world evidence (RWE), member states may revert to conducting their own parallel assessments. Such fragmentation could undermine the goal of harmonization and, more importantly, increase inequities in access for patients with rare diseases across different countries.¹⁹

These concerns illustrate a conflict at the core of the JCA model. On one hand, coordinated assessment promises consistency and efficiency. On the other, rare disease development depends heavily on various data sources, such as registries, natural history studies, and small, non-randomized trials. If these forms of evidence are not integrated into the assessment framework in a systematic way, the products most in need of regulatory and payer flexibility may face higher barriers to acceptance.

However, the JCA model did not emerge in isolation. It builds on earlier collaborative efforts among European HTA bodies, including initiatives such as EUnetHTA and regional partnerships like Beneluxa. These programs demonstrated both the feasibility and the challenges of joint assessment in areas of high uncertainty, particularly for innovative and high-cost therapies.²⁰ Regulation (EU) 2021/2282 formalizes this, transforming what were once voluntary networks into a structured policy mechanism.

Approval alone no longer defines success for ultra-rare therapies in Europe. Even when a product meets regulatory standards, its ability to achieve sustainable access depends on how its evidence is interpreted within coordinated HTA processes. For sponsors and manufacturing partners, the question of “how rare is too rare” is therefore inseparable from how uncertainty, real-world data, and clinical benefit will be judged across multiple health systems.

The U.S. Payer Response: Outcomes-Based Models

CMS Cell and Gene Therapy (CGT) Access Model

As ultra-rare therapies move from regulatory approval to real-world use, the question of how they are paid for has become as consequential as how they are approved. In the United States, this challenge is most visible in Medicaid, where high-cost, one-time cell and gene therapies intersect with budget constraints and state-level variability. In response, the Centers for Medicare & Medicaid Services (CMS) has introduced the Cell and Gene Therapy (CGT) Access Model, a voluntary program designed to test outcomes-based agreements for these products.

Under the model, CMS negotiates agreements with participating manufacturers in which payment is linked to whether a therapy achieves defined health outcomes in Medicaid beneficiaries. The stated goals are to improve patient access, increase affordability for state Medicaid programs, and reduce uncertainty around clinical performance in routine practice.³ Rather than leaving each state to negotiate independently, the program centralizes key terms, including pricing discounts and outcomes-based rebates, which then form the basis for contracts between manufacturers and participating states.

Two early participants illustrate the model’s initial scope. CMS announced agreements with Vertex and bluebird bio, positioning their gene therapies as test cases for this approach to coverage and payment.²¹ Operationally, the model is scheduled to launch in January, with states able to opt in over a multi-year window extending through 2026.²² This structure reflects an acknowledgment that adoption will require time for state Medicaid agencies to align clinical, administrative, and financial processes around outcomes-based contracting.

For developers of ultra-rare and genetically targeted therapies, the CGT Access Model demonstrates a shift in how commercial risk is shared. Instead of relying solely on upfront payment tied to regulatory approval, manufacturers enter arrangements in which reimbursement is explicitly connected to real-world patient outcomes. In doing so, the federal government has created a formal mechanism to manage both clinical uncertainty and budget impact for therapies that may serve only a small number of patients but carry very high per-patient costs.

Medicaid Best Price Reform

The CGT Access Model builds on earlier changes to Medicaid drug payment rules that were intended to make outcomes-based contracting possible in the first place. Historically, the Medicaid Drug Rebate Program’s “best price” requirement discouraged manufacturers from offering performance-linked discounts, because a single deeply discounted transaction could reset the lowest price nationwide. To address this barrier, CMS revised its rules to allow manufacturers to report multiple best prices when those prices are associated with qualifying value-based purchasing arrangements that are made available to all states.

Beginning July 1, 2022, manufacturers have been permitted to structure agreements in which different prices or rebates apply depending on whether a drug achieves specified clinical outcomes. These arrangements can include additional rebates or price concessions tied directly to patient response, rather than a single fixed transaction price.²³ The change was framed by CMS as part of a broader effort to modernize Medicaid prescription drug purchasing and create flexibility for new payment models that better align cost with value.

Instead of treating approval as the endpoint of evidence generation, Medicaid payment policy now embeds ongoing performance assessment into reimbursement itself. For ultra-rare disease therapies, particularly cell and gene therapies, this approach reframes commercial viability as a function of demonstrated outcomes over time rather than a one-time transaction at launch. The U.S. payer response suggests that ultra-rare therapies are no longer evaluated solely on whether they can be afforded, but on whether their clinical impact can be measured and linked to payment in a structured way.

Value Assessment in Ultra-Rare Disease

ICER’s Modified Framework

As regulatory pathways and payment models have adapted to the realities of ultra-rare disease development, value assessment bodies have also reexamined how benefit should be defined and measured for therapies serving extremely small populations. One of the most visible examples is the modified framework developed by the Institute for Clinical and Economic Review (ICER) specifically for treatments targeting ultra-rare diseases.

ICER created this framework through a structured, nine-month public engagement process that involved patient communities, industry representatives, clinicians, and payers. The goal was not to exempt ultra-rare therapies from value assessment, but to recognize that conventional approaches, which were largely designed around common diseases and large clinical trials, may fail to capture dimensions of benefit that matter most in very small, high-need populations.²⁴

A central feature of ICER’s ultra-rare adaptation is its explicit inclusion of factors that extend beyond direct clinical endpoints. In addition to patient-level health outcomes, the framework calls for consideration of impacts on families and caregivers, acknowledging that rare diseases often impose substantial burdens on household functioning, employment, and long-term care needs. These effects, while difficult to quantify in traditional cost-effectiveness models, are treated as legitimate components of value in the ultra-rare context.²⁵

The framework also introduces the concept of “infrastructure of care” as a relevant dimension of assessment. For diseases with no existing treatments, the introduction of a first-in-class therapy can require the creation of entirely new diagnostic pathways, clinical expertise, and monitoring systems. ICER’s approach recognizes that these structural changes are part of what distinguishes ultra-rare disease innovation from incremental advances in more established therapeutic areas.

Importantly, this modified framework does not abandon rigor; it reframes it. By broadening the categories of impact under review, ICER signals that value in ultra-rare disease cannot be judged solely by the same metrics used for large-population therapies. Instead, it must account for the unique clinical, social, and system-level consequences of intervening in conditions where unmet need is profound and evidence is necessarily limited.

In this sense, ICER’s work parallels regulatory and payer developments described earlier. Just as agencies have adjusted evidentiary expectations and Medicaid has experimented with outcomes-based payment, value assessment has evolved to reflect the realities of ultra-rare disease development. Together, these shifts suggest that the question of viability is no longer confined to whether a therapy works, but whether its full range of effects can be understood and justified within emerging evaluation frameworks designed specifically for very small patient populations.

Synthesis: What “Too Rare” Means Now

Across regulatory, assessment, and payment systems, the meaning of “too rare” has shifted from a question of scientific feasibility to one of structural readiness. In the European Union, ultra-rare and cell and gene therapy products are increasingly routed into standardized clinical assessment through the JCA framework established under Regulation (EU) 2021/2282. The phased rollout — beginning with cancer therapies and advanced therapy medicinal products, followed by orphan medicines and then all other eligible products — signals that coordinated evaluation of clinical evidence will become a routine part of the pathway for precisely those innovations most associated with very small patient populations.^2,19

This change reframes how success is determined after authorization. Approval alone no longer defines viability; the interpretation of evidence through a shared assessment process now shapes how national systems judge benefit and uncertainty. For ultra-rare indications, where trials are small and endpoints are often surrogate or registry-based, the ability of JCA to accommodate real-world and nontraditional evidence will influence whether harmonization leads to access or fragmentation.^19,20

In the United States, a parallel shift is occurring on the payer side. Medicaid is no longer treating regulatory approval as the endpoint of evidence generation for ultra-rare and cell and gene therapies. Through the CMS Cell and Gene Therapy Access Model, outcomes-based contracts are being tested in which payment is linked directly to patient results, with the federal government negotiating key terms on behalf of participating states.^3,21,22 These efforts build on earlier reforms that allow multiple best prices and outcomes-based rebates within the Medicaid Drug Rebate Program, explicitly creating space for value-based purchasing arrangements tied to clinical performance rather than fixed transaction prices.^23,27

At the same time, independent evaluation bodies have formalized distinct approaches for ultra-rare disease therapies. The development of a modified value assessment framework specifically for ultra-rare conditions reflects recognition that conventional metrics do not fully capture the clinical and social dimensions of benefit in very small populations. By incorporating caregiver impacts and changes to the infrastructure of care, this framework treats ultra-rare disease innovation as qualitatively different from incremental advances in common diseases.^24,25

From “How Rare Is Too Rare?” to “What Infrastructure Makes It Viable?”

The evolution of ultra-rare disease development suggests that rarity alone is no longer the decisive factor. What now determines feasibility is whether the surrounding systems are equipped to support therapies designed for extremely small populations. Evidence strategies must adapt to limited enrollment and heterogeneous disease courses. Health technology assessment pathways must interpret that evidence in ways that are consistent across jurisdictions. Payment models must link reimbursement to outcomes in environments where uncertainty is unavoidable.

In this context, viability is more a matter of infrastructure rather than one of prevalence. Regulatory guidance has expanded to accommodate alternative trial designs and data sources. HTA frameworks have been reorganized to provide coordinated clinical evaluation at the regional level. Payers have begun to experiment with contracts that continue evidence generation after approval. Each of these components addresses a different dimension of the same problem: how to translate small numbers of patients and limited datasets into decisions that are credible, repeatable, and sustainable.

This reframing also changes how industry, investors, and manufacturing partners must evaluate ultra-rare programs. The question is no longer whether a disease is too rare to justify development but whether the necessary systems are in place to carry a therapy from discovery through assessment and into practice. That includes registries and natural history studies, standardized clinical evaluation processes, and payment structures capable of managing both uncertainty and cost.

Ultra-rare status is therefore no longer a binary. It is a systems question that spans trial design, regulatory review, value assessment, and reimbursement. The renewed debate over “how rare is too rare” reflects this convergence. As policies and pathways continue to evolve, the more practical question becomes what infrastructure is required to make ultra-rare therapies not only approvable, but accessible.